Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies

Kian Huat Lim, Yibin Yang, Louis M. Staudt

Research output: Contribution to journalArticle

101 Scopus citations


Derangement of the nuclear factor κB (NF-κB) pathway initiates and/or sustains many types of human cancer. B-cell malignancies are particularly affected by oncogenic mutations, translocations, and copy number alterations affecting key components the NF-κB pathway, most likely owing to the pervasive role of this pathway in normal B cells. These genetic aberrations cause tumors to be 'addicted' to NF-κB, which can be exploited therapeutically. Since each subtype of lymphoid cancer utilizes different mechanisms to activate NF-κB, several different therapeutic strategies are needed to address this pathogenetic heterogeneity. Fortunately, a number of drugs that block signaling cascades leading to NF-κB are in early phase clinical trials, several of which are already showing activity in lymphoid malignancies.

Original languageEnglish
Pages (from-to)359-378
Number of pages20
JournalImmunological Reviews
Issue number1
StatePublished - Mar 1 2012
Externally publishedYes


  • B-cell receptor
  • CARD11
  • Lymphoma
  • Multiple myeloma
  • MyD88

Fingerprint Dive into the research topics of 'Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies'. Together they form a unique fingerprint.

  • Cite this